Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04912050 · ClinicalTrials.gov registry record
EXtension of Tablo TrEatmeNt Duration Registry
A clinical trial, sponsored by Outset Medical.
- Completed
- Registry status
- 33
- Enrollment target
NCT04912050 is a clinical trial that has completed, run by Outset Medical. The registered enrollment target is 33 participants.
The verdict
NCT04912050 has completed, sponsored by Outset Medical.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.
Interventions
- DEVICE Tablo Hemodialysis System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2022-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04912050
The ClinicalTrials.gov registry entry for NCT04912050 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Outset Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tablo Hemodialysis System is the first listed.
NCT04912050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04912050 about?
NCT04912050 is a clinical study titled "EXtension of Tablo TrEatmeNt Duration Registry". Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.
What is the current status of trial NCT04912050?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2021-05-25. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04912050?
The interventions under investigation include: Tablo Hemodialysis System (DEVICE).
Who is sponsoring clinical trial NCT04912050?
This trial is sponsored by Outset Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.